Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma
…, LB Nabors, JB Fiveash, S Shen… - Journal of Clinical …, 2006 - ascopubs.org
Purpose TM-601 binds to malignant brain tumor cells with high affinity and does not seem to
bind to normal brain tissue. Preclinical studies suggest that iodine-131 ( 131 I) –TM-601 …
bind to normal brain tissue. Preclinical studies suggest that iodine-131 ( 131 I) –TM-601 …
Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
RF Meredith, J Torgue, MT Azure, S Shen… - Cancer Biotherapy …, 2014 - liebertpub.com
Purpose: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) 212 Pb-TCMC-trastuzumab
in patients with HER-2-expressing malignancy. Experimental Design: IP 212 …
in patients with HER-2-expressing malignancy. Experimental Design: IP 212 …
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
…, DB Axworthy, HB Breitz, RB Sims, RG Ghalie, S Shen… - Blood, 2004 - ashpublications.org
Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide
delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 …
delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 …
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab
R Meredith, J Torgue, S Shen… - Journal of Nuclear …, 2014 - jnm.snmjournals.org
Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity, and
tumor response of intraperitoneal 212 Pb-TCMC-trastuzumab (TCMC is S-2-(4-…
tumor response of intraperitoneal 212 Pb-TCMC-trastuzumab (TCMC is S-2-(4-…
Imaging glioma extent with 131I-TM-601
DC Hockaday, S Shen, J Fiveash… - Journal of Nuclear …, 2005 - jnm.snmjournals.org
TM-601, a 36-amino-acid peptide, selectively binds to glioma cells but not normal brain
parenchyma. A phase I/II clinical trial of intracavitary 131 I-TM-601 in adult patients with recurrent …
parenchyma. A phase I/II clinical trial of intracavitary 131 I-TM-601 in adult patients with recurrent …
[PDF][PDF] Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung
S Shen, GL DeNardo, A Yuan… - Journal of Nuclear …, 1994 - jnm.snmjournals.org
MATERIALS AND METHODS Detector System and CollImation Two gamma cameras, a ZLC-7500
Orbiter (Siemens Medical Systems, Inc., Des Plaines, IL) with a circular (39-cm …
Orbiter (Siemens Medical Systems, Inc., Des Plaines, IL) with a circular (39-cm …
Maximum-tolerated dose, toxicity, and efficacy of (131) I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
…, NB Levy, JP McGahan, Q Salako, S Shen… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes,
has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with …
has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with …
A Phase I Study of Combined Modality 90Yttrium-CC49 Intraperitoneal Radioimmunotherapy for Ovarian Cancer
…, LC Kilgore, WE Grizzle, S Shen… - Clinical Cancer …, 2002 - aacrjournals.org
Purpose: The purpose of this study was to determine the feasibility and maximum tolerated
dose of 90 Yttrium-CC49 ( 90 Y-CC49) as the radioimmunotherapy (RIT) component of an ip …
dose of 90 Yttrium-CC49 ( 90 Y-CC49) as the radioimmunotherapy (RIT) component of an ip …
[PDF][PDF] A Clinical trial of radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin's lymphoma
…, DL Kukis, KR Lamborn, S Shen… - Journal of Nuclear …, 1999 - jnm.snmjournals.org
Resufts: 67Cu-2lT-BAT-Lym-1providedgoodimagingof NHL and favorable radiation dosimetry.
The mean radiation ratios of tumor to body and tumor to marrow were 28: 1 and 15: 1, …
The mean radiation ratios of tumor to body and tumor to marrow were 28: 1 and 15: 1, …
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
…, LA Hammond, A Patnaik, ML White, S Shen… - Clinical cancer …, 2004 - aacrjournals.org
Purpose: To determine the feasibility of administration, safety, toxicity, immunogenicity,
pharmacokinetics, maximum tolerated dose, and biodistribution of ING-1, a high-affinity, Human-…
pharmacokinetics, maximum tolerated dose, and biodistribution of ING-1, a high-affinity, Human-…